Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
“Listen the rhythm, before it pauses”
The Cardiology series of Allied Academies Conferences and its associated journals coordinate welcome the knowledge seekers to immerse themselves in the emerging field of Cardiology. We at Allied Academies, always have the extreme prospective of covering the expansive range of topics in cardiology. The growing enthusiasm for the various fragments of Cardiology and CardiacSurgery has accelerated the Novel Insights of the clinical experiments and the topical comprehensive medication in Cardiological Disorders.
The mainframe of Cardiology Conferences is to bring the opportunity to theglobal cardiologists, cardiacsurgeons and researchers to deliver the newer and advance medicalapproaches for the purpose of endeavouring in spreading technical and researchadvances in the clinical, diagnostic and physiological aspects of cardiology.
Each of our Conferences have crammed with Pre ConferenceWorkshop, followed by Keynote Presentation, Oral Presentation, PosterPresentation, and Young Researchers Forum.
We value your time and commitments towards your profession.And it helps us to promote the Video Presentation session and E-Poster sessionfor the Committed Professionals over time and Venue.
Coming to the scope of the cardiology sector, according to anew report the global cardiology market size was valued at USD 116.9 billion in2017 and is expecting a growth of 7.4% over the determined forecast time periodof 2018-2023. Raising of the generality of Congenital Heart Disease and thepresence of technologically advanced cardiac surgery and valves, grafts, &patches are among the fundamental factors expected to drive over the estimatetime frame.
Another WHO report in May 2018, the mortality rate of thepopulation in Japan, UK, USA, Canada, and Australia is due to the increase incardiology diseases. With new drugs and devices entering the market, there israpid innovation in the global cardiology therapeutics market. Diabetes isconsidered one of the leading factors to the current cardiovascular diseaseepidemic, according to a recent report on cardiology market research experts.The growing number of chronic diseases such as diabetes is the major sectionleading to the growth of the cardiology failure market. There will be anexpected growth in the cardiology market in the upcoming years due to thepotential breakthrough of newly authorized drugs in the world market.
The AlliedAcademies Conferences are working boundlessly to deliver the cardiologicscientific progression in an ultimately different level; the world has neverapproached before. So once again we are welcoming all to participants to attendCardiology Conferencesand witness the scientific Evolution in Cardiological medication.
Cardiology
Conference | Cardiology Conferences
| Arrhythmia
Conference | Congenital heart disease
Conference | Coronary Artery
Disease Conference | Cardiomyopathy
Conference | Vascular disease
Conference | Stroke Conference | Heart Failure Conference | Hypertension Conference | Rheumatic heart disease |
Cardiology Events | Cardiology Meetings
Cardiology
is a branch of internal
medicine which deals with the most sensitive internal organ heart. Cardiology includes
the research of diagnosis, treatment and prevention of the heart diseases and
the arteries or veins which are connected to the heart. There are many sub
specialities of cardiology
such as echocardiography, cardiac electrophysiology, nuclear cardiology and interventional
cardiology. As we all know the basic functioning of the blood pump or
cardiovascular system includes the path where the heart supplies the oxygen and
nutrients in the blood, which is generally called as coronary circulation.
Cardiovascular system consists of a range of disorders which
are treated and is been studied in the field of cardiology. In those
cases the major one is acute coronary syndrome which has a broad range of
spectrum in myocardial infarction symptoms. Few commonly occurring disorders
are atherosclerosis,
coronary heart disease, Angina pectoris and restenosis. When seen in broader
categories of complex disorders in the filed of cardiology includes
cardiac arrest, myocardium disorders, spasm of heart tissues, cardiomyopathy,
pericardium disorders of heart or swelling in the outer lining of the heart
that may include the various types of pericarditis, heart valve diseases which
includes aortic valve, mitral valve, pulmonary valve, tricuspid valve etc.
Whereas congenital heart defects which are ranging from atrial septal to
ventricular sepal defect are the most common ones in the disorders occurring
frequently. Diseases of the vascular diseases or blood vessels, in which they
include the disorders like deep vein thrombosis, aneurysm, vasculitis, and
varicose veins and blood vessels diseases.
Cardiologists
are the Specialists in cardiology. Cardiologists uses
some of the strategies to combat cardiovascular conditions include percutaneous
trans luminal angioplasty, percutaneous coronary intervention, coronary roadway
bypass surgery, and stenting. Cardiologists also
may diagnose cardiovascular diseases using blood tests, cardiac stress tests, echocardiography
or electrocardiography or reckoned tomography and glamorous resonance imaging
ways
The global market size of cardiology in 2020
was valued upto 10.11 billion down from nearly 15 billion in 2019 which is due
to the hit of covid19 all over the globe. The cardiology global
market size was normally expected to reach nearly 18 billion in 2027. In that
45% of global cardiology
market size was owned by the companies like Boston Scientific, Abbott and
Medtronic. More than 70 countries in the world includes in analysis of 50
interventional cardiology
companies jumping right into the market.
COVID19 impact
After the hard hit of covid19 in 2019 the cardiology market
got reduced to 25% from 2019 reaching with a valuation of 12.1 billion in 2020.
Cardiology market
is being expected to increase again after 2022 and will be in steady pace of
growth in forthcoming years.
In 2019 million of the patients all around the globe had a
delayed care as the hospitals cancelled or postponed non-urgent operations,
which is including some of the surgeries for people with heart, kidney and lung
conditions. Which as a result, every region around the globe had experienced
low numbers of records for the angiographies and the angioplasties in 2020
For an example, in the beautiful city of the Spain,
procedures like angioplasty were really very down by 50% within the first two
weeks of the lockdown in March and April. But there were also 44.8% low
diagnostic examinations and 80.1% fewer procedure like Trans catheter
interventions. One of Italy’s worst affected regions Lombardy shuts down 79.8%
of the cardiac surgical units in order to preserve their resources for the
upcoming emergency in COVID-related cases.
Boston Scientific is one of the leading competitors in the
global cardiology
market for interventional cardiology devices productions and supply in 2020.
This is the company which was the leader of the market in the coronary balloon
catheters, coronary embolic protection devices and coronary atherectomy devices
markets. The company of Boston Scientific offers the Flextome cutting balloon
catheter to the companies like Maverick, Apex, and Emerge PTCA devices.
Abbott was one of the alternate commanding contenders in the
global interventional cardiology
request. The company held notable positions in the interventional coronary
guidewire, coronary stent, FFR guidewire (within the individual coronary
catheter and guidewire request), and OCT catheter requests. Medtronic was the
third leading contender in the global request in 2020. The company performed
the strongest in the interventional coronary catheter request, where it offered
the Launcher, Sherpa NX Active, and Sherpa NX Balanced product lines under its
portfolio.
Regional insights
Cardiovascular bias is used for the opinion of heart
conditions and treatment of affiliated health problems. The cardiovascular bias
request is segmented by device type and terrain. On the base of device type,
the request is segmented into individual and monitoring bias and remedial and
surgical bias. The individual and monitoring bias member is segmented into electrocardiogram
(ECG), remote cardiac monitoring, and other individual and monitoring bias.
Remedial and surgical bias are segmented into cardiac help bias, cardiac meter
operation bias, catheters, grafts, heart faucets, stents, and other remedial
and surgical bias. By terrain, the request is segmented into North America,
Europe, Asia-Pacific, Middle-East and Africa, and South America. The request
report also covers the estimated request sizes and trends for 17 different
countries across major regions encyclopaedically. The report offers the value
(in USD million) for the below parts.
Leading Cardiology devices
manufacturing Companies are
The sector also has good prospects for the future growth, as
well. EvaluateMedTech projects that the sector will grow at a compound annual
growth rate of 5.1% from 2015 to 2020--one of the healthiest growth rates of
any medtech niche.
The sector dominated when it came to the 50% year-over-year
increase in PMAs that the medical device industry experienced during the first
eight months of 2015, according to EvaluateMedTech (Boston). Worldwide sales in
the sector are expected to grow 4.4%, to $54.2 billion, by 2020, with cardiology's share
of the global device market ticking up two-tenths of a percentage point to
11.4%.
Cardiology
Conference | Cardiology Conferences
| Arrhythmia
Conference | Congenital heart disease
Conference | Coronary Artery
Disease Conference | Cardiomyopathy
Conference | Vascular disease
Conference | Stroke Conference | Heart Failure Conference | Hypertension Conference | Rheumatic heart disease |
Cardiology Events | Cardiology Meetings
Here are the 10 companies that Evaluate MedTech expects will lead the
cardiology space
by 2020, along with descriptions of how their businesses are evolving:
Rank |
Company |
2020
Sales (Projected) |
2014
Sales |
%
Change |
1. |
Medtronic |
$12.001B |
$8.531B |
+3.4% |
2. |
St. Jude
Medical |
$6.386B |
$4.985B |
+3.6% |
3. |
Boston
Scientific |
$6.106B |
$5.046B |
+3.3% |
4. |
Edwards
Lifesciences |
$4.018B |
$3.189B |
+7.5% |
5. |
Abbott
Laboratories |
$3.219B |
$2.944B |
+1.9% |
6. |
Johnson
& Johnson |
$2.1200B |
$2.208B |
+2.9% |
7. |
Getinge |
$2.014B |
$2.721B |
+3.1% |
8. |
Terumo |
$2.002B |
$1.778B |
+4.6% |
9. |
W. L.
Gore & Associates |
$1.006B |
$1.559B |
+3.7% |
10. |
Lepu
Medical Technology |
$1.002B |
$201M |
+27.2% |